Arcutis Biotherapeutics, Inc. (ARQT) Tops Q1 EPS by 1c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($0.20), $0.01 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $65.8 million versus the consensus estimate of $63.66 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• BofA maintains underperform ratings on six BDC stocks
• BofA says CTA Treasury shorts stable, euro short-cover risk rises
• Boeing names Ryan Shedd as new SVP and controller